ZANOSAR, known generically as streptozocin, is a chemotherapy medication primarily used in the treatment of pancreatic cancer, specifically in cases involving islet cell tumors or pancreatic neuroendocrine tumors. It belongs to the class of drugs known as alkylating agents, which work by damaging the DNA of cancer cells, thereby inhibiting their growth and multiplication. ZANOSAR is administered intravenously and is notable for its ability to selectively target pancreatic cancer cells, offering a therapeutic option for a particularly challenging type of cancer. Due to its potent effects and the potential for significant side effects, its use is carefully monitored by healthcare professionals in a clinical setting.